Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 2L • 2015 ACR/ARHP Annual Meeting
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
Peter C. Taylor¹, Edward C. Keystone^2,3, D. van der Heijde⁴, Yoshiya Tanaka⁵, Taeko Ishii⁶, Kahaku Emoto⁶, Lili Yang⁶, Vipin Arora⁶, Carol L. Gaich⁶, Terence Rooney⁶, Douglas E. Schlichting⁶, William Macias⁶, Stephanie de Bono⁶ and Michael E. Weinblatt⁷, ¹Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Brigham and Women’s Hospital, Boston, MA
Background/Purpose: In phase 3 studies, baricitinib (bari) improved disease activity in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs1…
Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Joel M. Kremer¹, Edward C. Keystone², Paul Emery³, Heidi S. Camp⁴, Alan Friedman⁴, Li Wang⁴, Ahmed A. Othman⁴, Nasser Khan⁴ and Steven Jungerwirth⁴, ¹Albany Medical College, Albany, NY, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…
Abstract Number: 1773 • 2015 ACR/ARHP Annual Meeting
Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway
Keigo Ikeda^1,2, Kunihiro Hayakawa², Maki Fujishiro³, Mikiko Kawasaki³, Takuya Hirai^2,4, Shinji Morimoto^2,4, Yoshinari Takasaki⁵ and Iwao Sekigawa^3,4, ¹Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ²Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: We previously reported that Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway-mediated regulation of interferon (IFN) regulatory factor (IRF)-related genes may have an…
Abstract Number: 1943 • 2015 ACR/ARHP Annual Meeting
Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis
Wenyan Miao¹, Craig Masse¹, Jeremy Greenwood², Rosana Kapeller¹ and William Westlin¹, ¹Nimbus Therapeutics, Cambridge, MA, ²Schrodinger Inc., New York, NY
Background/Purpose: Tyk2 is a member of the JAK family kinases and is a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines…
Abstract Number: 1945 • 2015 ACR/ARHP Annual Meeting
microRNA-30a Promotes the Inflammatory Response of Rheumatoid Arthritis By Regulating Th1 Cell Differentiation
Jing Zhang¹, HUA YE², Jianping Guo¹, Yan Du³, Mengru Liu¹ and Zhanguo Li⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²No.11 XIZHIMENG SOUTH STREET,, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ⁴Peking University People's Hospital, Beijing, China
Background/Purpose: In our previous study, the transcriptome profiles of CD4+T cells from 13 active RA cases and 9 healthy controls were accessed by microarrays. a…
Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population
Alan J Kivitz¹, Boulos Haraoui², Jeffrey Kaine³, Vanessa Castellano⁴, Eustratios Bananis⁴, Carol A Connell⁵, Elaine Hoffman⁵ and Liza Takiya⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…
Abstract Number: 485 • 2015 ACR/ARHP Annual Meeting
Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
Xin Zhang, Laiyi Chua, C. Steven Ernest II, William Macias, Terence Rooney and Lai San Tham, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari) is an oral inhibitor of Janus kinases (JAK) selective for JAK 1 and 2. It has demonstrated dose-dependent efficacy in patients with…
Abstract Number: 2730 • 2015 ACR/ARHP Annual Meeting
Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Paul Emery¹, Carol L. Gaich², Amy M. DeLozier³, Stephanie de Bono^2,4, Jiajun Liu², Cecile Chang² and Maxime Dougados⁵, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Cookham, United Kingdom, ⁵Paris-Descartes University, Paris, France
Background/Purpose: Baricitinib (bari) is an oral Janus kinase (JAK) 1 /JAK2 selective inhibitor, representing a potentially effective treatment for patients with moderately to severely active rheumatoid…
Abstract Number: 597 • 2015 ACR/ARHP Annual Meeting
JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients
Shintaro Hirata¹, Natasja Stæhr Gudman², Kentaro Hanami¹, Satoshi Kubo¹, Anne C. Bay-Jensen², Morten Asser Karsdal³ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Connective tissue degradation and formation is markedly increased in rheumatoid arthritis (RA). Increased tissue formation may result in fibrosis, whereas increased degradation may result…
Abstract Number: 2751 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition and Administration of High-Fat Meal on the Pharmacokinetics of the Potent and Selective JAK1 Inhibitor ABT-494
Mohamed-Eslam Mohamed¹, Steven Jungerwirth², Armen Asatryan¹, Ping Jiang² and Ahmed Othman¹, ¹AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL
Background/Purpose: ABT‑494 is an oral selective JAK1 inhibitor that is being developed for treatment of rheumatoid arthritis and Crohn’s disease. ABT-494 is metabolized by cytochrome…
Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…
Abstract Number: 2763 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers
Namour Florence¹, Béatrice Vayssière¹, René Galien², Liesbeth Fagard³, Annegret Van der Aa³, Sandy Goss⁴, Pille Harrison³ and Chantal Tasset³, ¹Galapagos SASU, Romainville, France, ²102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium, ⁴Abbvie, Chicago, IL
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining clinical efficacy and a rapid onset of action with a good safety profile…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…
Abstract Number: 2781 • 2015 ACR/ARHP Annual Meeting
Absence of Effects of Filgotinib on Erythrocytes, CD8+ and NK Cells in Rheumatoid Arthritis Patients Brings Further Evidence for the JAK1 Selectivity of Filgotinib
René Galien^1,2, Reginald Brys³, Annegret Van der Aa³, Pille Harrison³ and Chantal Tasset³, ¹Galapagos SASU, Romainville, France, ²102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: The distinct role of JAK family members (JAK1, JAK2, JAK3 and TYK2) in signaling for cytokines and growth factors has established these kinases as…
Abstract Number: 1047 • 2015 ACR/ARHP Annual Meeting
Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Paul Emery¹, Iain McInnes², Mark C. Genovese³, Josef S. Smolen⁴, Joel Kremer⁵, Maxime Dougados⁶, Douglas E. Schlichting⁷, Terence Rooney⁷, Maher Issa⁷, Stephanie de Bono⁷, William L. Macias⁷, Veronica Rogai⁷, Steven H. Zuckerman⁷ and Peter C. Taylor⁸, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Albany Medical College, Albany, NY, ⁶Paris-Descartes University, Paris, France, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari) is an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2 being developed as QD treatment for patients (pts) with RA. In phase (ph)…

« Previous Page
1
…
6
7
8
9
10
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].